Navigation Links
Tris Pharma Appoints New Vice President of Business Development
Date:11/15/2012

MONMOUTH JUNCTION, N.J., Nov. 15, 2012 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, announced the appointment of Jonathan Berlent as Vice President of Business Development.  He will lead Tris' product and technology partnering, and collaborate with branded pharmaceutical companies on their life cycle management opportunities. 

"As Tris scales up its effort to address the growing unmet need in the industry for liquid extended release technology, Jonathan will lead business development efforts and be our point person with branded pharmaceutical companies," said Ketan Mehta, President and CEO of Tris Pharma.  "With Jonathan leading business development, Peter Ciano will focus on strategy and corporate development activities including acquisitions."

"Tris is a pioneer in commercializing unique, sustained release formulations such as oral liquid suspensions, orally disintegrating tablets and chewable tablets that do not require patients to swallow a pill," said Berlent. "I am truly excited to be part of the Tris management team and look forward to leading business development efforts."

Jonathan brings to Tris a combination of pharmaceutical and securities industry experience.  For the past nine years, he has held various senior leadership positions in the pharmaceutical industry.  Most recently, he was President of Granules USA, Inc., where he led its North American operations and successfully launched a finished dosage business platform working with such companies as Pfizer, Novartis, McNeil Consumer Health Janssen, GlaxoSmithKline, Par and Perrigo.  He began his career in the capital markets at Bank of America.  He is an alumnus of the University of Michigan and has an MBA from NYU Stern School of Business, where he majored in finance and management.

About Tris Pharma:

Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, U.S.A.

For more information, please visit http://www.trispharma.com.


'/>"/>
SOURCE Tris Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
Breaking Medicine Technology:
(Date:4/27/2017)... ... ... Goodcents Deli Fresh Subs announced a franchise expansion agreement today including three ... The first new location will open at the corner of 27th and Randolph in ... Drive this fall. And the third location is in the process of being identified. ...
(Date:4/27/2017)... ... April 27, 2017 , ... Are you investing in the ... water-related accidents and drownings during the summer. While most of us assume this type ... occur every day. Very few people are taking the time to learn how to ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... management in hospitals, today announced it has completed a round of funding to ... LLC and its partners. Black Granite Capital is a growth equity firm focused ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... Journal ... adults. It can have severe consequences to overall dental health, including complications with speech, ... often turn to dental implants to replace lost teeth. As the number of tooth ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... the adoption of e-prescribing as measured in Part D Medicare data. The dataset, ... to pharmacies, either using e-prescribing, faxes or paper. The PaPR (pronounced "paper") ...
Breaking Medicine News(10 mins):